Lipodystrophy is characterised by an abnormal distribution of fat in the body
News
ConserV Bioscience to develop ‘broad-spectrum’ coronavirus vaccine
UK biotech company will collaborate with Lawrence Livermore National Laboratory
Enhertu bags EU approval for HER2-positive breast cancer
Approximately one in five breast cancer cases in the EU are HER2-positive
Tecartus wins NICE recommendation for mantle cell lymphoma
CAR-T therapy receives NICE backing within weeks of EMA authorisation
SMC kicks off the new year by accepting five new medicines for NHS use
Darzalex, Rozlytrek and Tavlesse among newly accepted drugs
Scotland’s pharma sector sees increase in research investment
Industry’s GVA has increased to $1.8bn according to new ABPI Scotland report
DHSC says over four million people have received first COVID-19 vaccine dose
NHS is now offering vaccines to another two priority groups in the UK
ViiV Healthcare continues HIV care partnership with Chelsea and Westminster Hospital
Partnership aims to transform HIV patient care with digital services
Xalkori bags FDA green light for rare paediatric non-Hodgkin lymphoma
Therapy approved for the treatment of paediatric patients with anaplastic large cell lymphoma
UK biotech Ixaka scores additional funding for cell and gene therapy research
Lead asset REX-001 is in Phase III development for chronic limb-threatening ischaemia
AZ, Daiichi Sankyo’s Enhertu wins US approval for HER2-positive gastric cancer
Approval is based on results from the Phase III DESTINY-Gastric01 trial
Verona completes enrolment in pilot study of potential COVID-19 inhaler
Ensinfentrine is a first-in-class inhaled inhibitor of the enzymes phosphodiesterase 3 and 4
Boehringer Ingelheim and Enara Bio join forces to discover cancer immunotherapies
Agreement will leverage Enara’s novel Dark Antigen discovery platform
NICE backs GSK’s Zejula in advanced ovarian cancer
Zejula has been recommended for use in newly diagnosed ovarian cancer patients
US breakthrough designation for ligelizumab in chronic spontaneous urticaria
In a Phase IIb trial, more patients experienced complete resolution of hives with ligelizumab compared to Xolair
